FDA
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
PTC Therapeutics receives FDA approval for PKU treatment drug
-
-
-
-
-
-
-
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $60 at TD Cowen Following FDA Acceptance and Priority Review for Vatiquinone NDA
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
-
-
-
-
-
-
-
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

